WEAVING A STRONGER FABRIC:

THE CRITICALITY OF DEVELOPING ROBUST ANALYTICAL METHODS IN HARMONY WITH EFFICIENT PROCESS DEVELOPMENT AT PHARMACEUTICAL CDMOS

By: Singota Solutions

Singota® Solutions is a CDMO located in Bloomington, Indiana, USA that specializes in Parenteral, Early Phase Drug Development and Aseptic Filling projects.

As drug developers navigate the journey from early product design to successful commercial product, it is important to invest in rigorous Analytical Method Development (AMD) plans. Among the many components of process development, AMD stands out as critical to ensure long-term product quality and regulatory compliance. A strong AMD design plays a pivotal role in the strategic delivery of product excellence throughout the drug development lifecycle. Analytical method development involves creating and optimizing methods for testing drug substances and products. Leading, modern Contract Development and Manufacturing Organizations (CDMOs) must anticipate the depth and breadth of AMD methods with an eye towards sustainable success within the larger picture of client process development. The data generated by analytical methods guides the refinement of manufacturing processes, ensuring that manufacturing process is optimized to consistently produce products that meet the Quality Target Product Profile (QTPP) specifications.

The Alignment of Analytical Methods and Process Development

The International Council for Harmonization (ICH) guidelines, particularly ICH Q14 and ICH Q8(R2), provide a framework for the integration of analytical method development with process development. ICH Q14 focuses on the development of analytical procedures, advocating for a science- and risk-based approach. It highlights the importance of understanding the purpose of the analytical method and the context in which it will be used, ensuring that it is fit for its intended purpose.

ICH Q8(R2) introduces the concept of Quality by Design (QbD) in pharmaceutical development, emphasizing the importance of understanding both the product and the process to ensure consistent quality. It encourages the integration of analytical methods with process development to ensure that the manufacturing process is capable of consistently delivering a product that meets its QTPP. The QTPP is a summary of the quality characteristics a drug product should possess, including safety, efficacy, and stability. This profile serves as a guiding document throughout the development process.

Critical Quality Attributes (CQAs) are the specific physical, chemical, biological, or microbiological properties that must be controlled to ensure that the product meets its QTPP. By following these guidelines, CDMOs can develop analytical methods that not only meet regulatory requirements but also enhance the efficiency and effectiveness of the process development.

Analytical methods are essential for monitoring and controlling CQAs during process development. By aligning analytical method development with the QTPP, CDMOs can ensure that their methods are specifically tailored to assess the most critical aspects of the product. This approach not only ensures product quality but also supports a more efficient and targeted development process. By tailoring analytical methods to the QTPP, CDMOs can concentrate on the most critical aspects of the product. The QTPP outlines the desired quality characteristics, such as potency, purity, and bioavailability, which are essential for the product's intended use. This focus ensures that analytical methods are developed to precisely measure and control the CQAs that have the most significant impact on product quality. As a result, any deviations from the desired quality attributes can be identified and corrected early in process development, ensuring that the final product consistently meets its quality targets.

Aligning analytical methods with the QTPP promotes a deeper understanding of the relationship between process development and the product's quality attributes. By developing methods that specifically monitor CQAs, CDMOs gain valuable insights into how different process parameters influence these attributes. This knowledge allows for the optimization of the process to maintain control over CQAs, leading to a more robust and reliable manufacturing process.

The work to identify and control critical CQAs allows the CDMO-client collaboration team to address observed potential issues proactively, reducing the likelihood of product failures or non-compliance with regulatory standards. This risk-based approach is in line with ICH Q14 and ICH Q8(R2), which emphasize the importance of understanding and managing risks throughout the development process.

When analytical methods are aligned with the QTPP, development efforts can be more efficiently directed towards the most critical areas of the process. This targeted approach minimizes unnecessary testing and resource allocation on less critical attributes, allowing CDMOs to focus their efforts on areas that have the greatest impact on product quality. This efficiency not only reduces development time and costs but also accelerates the overall time-to-market. By developing analytical methods that are closely aligned with the QTPP and CQAs, CDMOs ensure that the data generated during process development is directly relevant to regulatory submissions. Regulatory agencies require evidence that the product consistently meets its quality specifications. A well-aligned analytical method development process provides the necessary data to demonstrate compliance. This alignment simplifies the regulatory review process and reduces the risk of delays or rejections. As the process and product understanding deepen, analytical methods can be refined and optimized to better monitor CQAs. This continuous improvement cycle supports the evolution of both the manufacturing process and the product itself, leading to enhanced product quality over time. It also ensures that the methods remain relevant as the product progresses through different stages of development and commercialization.

The Strategic Benefits of Expertise in Analytical Method Development

Having professionals who are well-versed in both analytical method development and process development is a significant asset for any pharmaceutical CDMO. These individuals bring a deep understanding of the interplay between analytical methods, CQAs, QTPP, and regulatory guidelines. Their expertise offers the discerning client several strategic benefits:

1. Accelerated Time-to-Market: By ensuring that analytical methods are developed in tandem with the manufacturing process, organizations can reduce development timelines and bring products to market faster.
2. Enhanced Product Quality: Experts in analytical method development are adept at identifying and controlling CQAs, which directly impacts the quality and consistency of the final product.
3. Regulatory Advantage: A strong understanding of ICH guidelines ensures that analytical methods are not only effective but also compliant with global regulatory standards. This reduces the risk of regulatory setbacks and facilitates smoother approval processes.
4. Long-Term Organizational Success: Professionals with expertise in both analytical method development and process development contribute to a culture of quality and continuous improvement. This strategic focus on quality and compliance strengthens the organization's reputation and fosters long-term partnerships with clients.

Weaving it All Together

In summary, Analytical Method Development is a critical phase in the process development of pharmaceutical products. By integrating the AMD phase with the principles outlined in ICH Q14 and ICH Q8(R2), and by focusing on CQAs and the QTPP, CDMOs can ensure that their processes are robust, efficient, and compliant. Moreover, having professionals who are well-versed in both analytical and process development provides a strategic advantage to discerning clients, enabling organizations to meet their long-term goals of delivering high-quality pharmaceutical products to market quickly and effectively.

Singota Solutions is a US based CDMO in Bloomington, Indiana. Singota specializes in formulation development and aseptic fill finish for injectable projects. Once a formulation is established, Singota utilizes state of the art robotic filling technology and focuses on smaller batch size requirements. For more information, visit Singota.com to explore how Singota has established itself as a one-stop solution for all your developmental needs.

Contact **solutions@singota.com** to schedule a meeting with our business development team to further discuss your current or future projects.